Treating extrapyramidal syndrome using trapidil

Inventors

BORDBAR, Aarash

Assignees

Sinopia Biosciences Inc

Abstract

Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.

Core Innovation

The invention relates to a method for treating or preventing levodopa-induced dyskinesia in a subject by administering to the subject a Trapidil compound or a pharmaceutically acceptable salt thereof. The subject matter is specifically directed to levodopa-induced dyskinesia as the therapeutic target.

The disclosure includes Trapidil derivatives, metabolites, prodrugs, analogs, and pharmaceutically acceptable salts, with specific named forms such as AR12455, AR12456, AR12460, AR12463, AR12464, AR12465, and AR12565, and metabolites including desethyl-trapidil and TP1/TP2. It also includes a transcriptomic marker panel associated with ERK and related pathway modulation, including AP-1/ERK and cholesterol synthesis and cell-cycle markers such as FOSL2, JUN/JUND, ATF3, SREBF2, INSIG1, ERK, MYC, and BCL2.

The partial document further states a dosing and administration framework for Trapidil, including oral daily dose ranges, single versus multiple daily dosing, and intravenous or subcutaneous administration. It also describes combination therapy in which Trapidil is administered with additional therapeutic agents, including levodopa, with timing described as simultaneous or sequential and with fixed versus separate dosage forms.

Claims Coverage

The consolidated claim coverage centers on one independent claim directed to treating or preventing levodopa-induced dyskinesia by administering a Trapidil compound or a pharmaceutically acceptable salt, with several dependent refinements adding inventive features such as specific Trapidil derivatives, timing relative to levodopa, symptom characterization, daily dose range, and dosing frequency.

Coverage is centered on administering Trapidil or a pharmaceutically acceptable salt to treat or prevent levodopa-induced dyskinesia, with further constraints on selected Trapidil derivatives, timing relative to levodopa, symptom characterization, daily dose range, and dosing frequency.

Stated Advantages

Documented Applications